Latest Breaking News On - Once nightly sodium oxybate - Page 1 : comparemela.com

Avadel Pharma (AVDL) Announces Data Supporting Clinical Profile for LUMRYZ for extended-release oral suspension at World Sleep 2023

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Successfully commenced U.S. commercial launch of LUMRYZ™ Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 Significant early progress on payor coverage, prescriber certifications and patient enrollments Management to host a conference call today at 8:30 a.m. ET DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

– 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growing body of evidence demonstrating positive clinical benefit and patient. | June 10, 2023

Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting

Share: Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful results at 6 g, 7.5 g, and 9 g doses DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate (ON-SXB) for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced the presentation of positive secondary endpoint data at the 2021 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 17-22, 2021. FT218 is currently under review at the U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) target date of October 15, 2021.